Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Thymoma 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 24Magnetic Resonance Spectroscopy 10Carboplatin 8Nivolumab 7Docetaxel 7Paclitaxel 6Gemcitabine 6Trastuzumab 5Taxes 5Injections 5Fluorouracil 5Fluorodeoxyglucose F18 5Drug Therapy 5Cyclophosphamide 5Cisplatin 5fludarabine 4X-Rays 4Specimen Handling 4Radiotherapy 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Leucovorin 4durvalumab 3atezolizumab 3Surveys and Questionnaires 3Standard of Care 3Irinotecan 3Immunohistochemistry 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × FANG vaccine × Thoracic × Clear all
NCT01258868 2019-12-03

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
44 enrolled
GastrointestinalOther solid neoplasmThoracic

Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡